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Abstract
NF-κB was discovered thirty years ago as a rapidly inducible transcription factor. Since that time 
it has been found to have a broad role in gene induction in diverse cellular responses, particularly 
throughout the immune system. Here we summarize elaborate regulatory pathways involving this 
transcription factor and use recent discoveries in human genetic diseases to place specific proteins 
within their relevant medical and biological contexts.
Introduction
Thirty years ago, Ranjan Sen and one of the authors did a series of experiments that 
identified a protein binding to a specific, conserved DNA sequence in nuclei of activated B 
lymphocytes (Sen and Baltimore, 1986). We named it for the cell type in which we 
identified it and the gene it affected: Nuclear Factor binding near the κ light chain gene in B 
cells, or NF-κB. Had we realized that NF-κB would have a wide role in inflammation and 
other natural and pathological processes, we might have found a simpler designation for ease 
of typing.
Because NF-κB was induced during B cell maturation, we suspected that it had a major role 
in B cell activation and development. This has proved true but it greatly underestimated the 
impact of NF-κB on biological systems (Baltimore, 2011; Hayden and Ghosh, 2008). First 
of all, it constitutes a paradigm of a rapid response factor, one held in latency in the cell 
(Figure 1). When an inflammatory or other insult impinges on a cell, it activates a whole 
pathway of orderly responses, starting immediately after stimulation. Once resolution of the 
stimulus is achieved, the pathway resets to latency. Second, not just B cells are activated; 
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perhaps more importantly, cells of the innate immune system are the first to be activated 
through NF-κB at a wound or site of infection (Ben-Neriah, 2002). These cells provide the 
first line of defense, especially to bacterial invaders. Many minor incursions are cleared 
solely by innate immunity in mammals; for lower organisms, the innate system may be their 
only defense. More extensive inflammation will activate B and T cells of the adaptive 
immune system, again with the heavy involvement of NF-κB.
As time has passed, what seemed a simple induction process mediated by such 
proinflammatory molecules as TNF or lipopolysaccharide has turned out to involve many 
intermediate factors and processes including protein-protein dimerization, phosphorylation 
of serine, threonine or tyrosine residues and polyubiquitin modifications (Hayden and 
Ghosh, 2008, 2012). Many inducers are known, each seemingly working through its 
individual pathway. Also, we have appreciated that NF-κB is not a single transcription 
protein but rather a family of related protein complexes working as hetero- and homo-
dimers, drawing from a pool of 5 monomers, yielding up to 15 NF-κB complexes (Smale, 
2012).
The remarkable capability of NF-κB to alter a cell’s biology results from hundreds of target 
genes that it activates or represses. Even with 15 potential forms, this is a daunting task 
because each component is needed at a characteristic concentration and time following 
inflammatory challenge. We know now that there is specificity information all around the 
target genes, from which other transcription factors may be bound along with NF-κB, to the 
specific binding site sequence and its effect on the detailed structure of NF-κB, to the 
particular form of NF-κB that best binds to a particular site, to the intrinsic half-life of the 
induced mRNA and to the rate of splicing of the induced pre-mRNA (Hayden and Ghosh, 
2012). This is a rich field of biology, not yet fully plumbed.
In the following presentation, we will review the detailed molecular biology of NF-κB-
mediated signaling. Against this background of understanding, we will then discuss 
mutational evidence for NF-κB’s function in particular situations, contrasting human genetic 
data with mouse studies and highlighting the differences between these two mammalian 
species. With such interesting differences, we can confidently predict that all species will, 
over time, have adapted the proteins we describe to their individual biology and ecological 
challenges, leaving much detail to be uncovered.
Biochemistry
Hundreds of genes utilize NF-κB through variations of a nearly palindromic DNA sequence 
with a consensus of 5′ –GGGRNWYYCC – 3′ (N – any base; R - purine; W – adenine or 
thymine; and why – pyrimidine), termed κB, found in their enhancers or promoters 
(Gilmore, 2016 http://www.bu.edu/nf-kb/gene-resources/target-genes/) (Sen and Baltimore, 
1986; Lenardo et al., 1987). The site binds dimers of 5 proteins comprising the Rel 
transcription factor family: p50, p52, Rel A (p65), Rel B, and c-Rel that share N-terminal 
homology with the v-Rel oncogene (Hayden and Ghosh, 2008)(Figure 2A). The Rel 
homology domain (RHD) is 300 amino acids and has 3 functions: sequence specific DNA-
binding, dimerization, and inhibitory protein binding (Hayden and Ghosh, 2012; Smale, 
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2012). The RHD contains 2 subdomains with beta-barrel immunoglobulin (Ig)-like folds. 
The N-terminal subdomain resembles the p53 DNA-binding domain and specifies DNA 
recognition. The C-terminal subdomain has hydrophobic residues that form dimerization and 
inhibitory protein interfaces. The domains are joined at a hinge that clamps onto both sides 
of the cognate κB site across the major groove of the DNA. Following the RHD is a nuclear 
localization sequence (NLS) (Figure 2A). The 5 Rel family proteins fall into 2 classes. First, 
p50 and p52 arise from precursor proteins, p105 (NFKB1) and p100 (NFKB2), respectively, 
from which a C-terminal region containing ankyrin repeats (AnkR) is post-translationally 
cleaved. Second, Rel A, Rel B, c-Rel, are synthesized as mature proteins with transcription 
transactivation domains (TADs). The two paradigmatic dimers are p50:p65 and p52:RelB, 
although other combinations including p50:p50 and p52:p52 homodimers or p52:RELA or 
p50:RELB heterodimers exist with distinct functions (Smale, 2012). All-in-all, 13 of the 15 
potential NF-κB family complexes have been demonstrated; the other 2 being undescribed 
and possibly unfavored (S. Ghosh, personal communication). TAD-containing heterodimers 
are transcriptional activators whereas p50 or p52 homodimers are repressors unless bound to 
secondary proteins. Since dimer combinations may recognize distinct variants of the κB site 
with different affinities, many gene regulatory patterns can be generated from this handful of 
proteins.
In unstimulated cells, such as “resting” lymphocytes before antigen encounter, NF-κBs are 
mainly cytoplasmic due to the binding of a dedicated set of inhibitory proteins comprising 
the “Inhibitor of κB” (IκB) family (Hayden and Ghosh, 2008). The intricate biochemical 
pathways controlling NF-κB/inhibitor complexes that have been reviewed authoritatively 
and we will only provide a brief summary (Hayden and Ghosh, 2012). The inhibitors, IκBα, 
IκBβ, IκBε, BCL-3, IκBz, IκBNS and the C-terminal portions of the precursor proteins 
p105 (IκBγ) and p100 (IκBδ), all contain 5–7 tandem ankyrin repeats (AnkRs) (Figure 2B). 
AnkRs are 33 amino acid ankyrin-like protein-protein association domains that extend as 
helices capable of binding to NF-κB covering the NLS. The C-terminal AnkR-containing, 
IκB-like regions of p100 and p105 undergo limited proteolysis to make p52 and p50 which 
transit to the nucleus. For p50, this occurs constitutively, but p52 is only generated after 
specific signaling events. The canonical p50/p65 heterodimer is regulated principally by 
IκBα (Figure 2C). Biochemical control of nuclear localization via IκB has two strategic 
consequences: 1) it becomes a principal control point for NF-κB-induced gene expression 
and, 2) it enables the preformed NF-κB transcription complexes to be launched into action 
instantaneously providing a rapid molecular switch for responses to pathogens or 
inflammatory stimuli. NF-κB also embodies an interesting developmental paradigm at least 
for B cells. One conceptual problem with tissue specific gene expression is an infinite 
regression paradox. If a tissue-specific transcription factor (TSTF) is required for a set of 
tissue-specific genes, then does TSTF itself require a TSTF and so on? The NF-κB paradigm 
shows that lineage and developmental transcriptional regulators can be induced 
biochemically, thereby resolving the paradox.
The first step of NF-κB activation involves post-translational modification of IκB inhibitors. 
This occurs by a canonical pathway (CP) and an alternative pathway (AP) (Hayden and 
Ghosh, 2008). For the CP, a kinase complex called IκB kinase (IKK) specifically 
phosphorylates IκB proteins leading to their degradation (Ben-Neriah, 2002). This causes 
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NF-κB dimers, which actively shuttle between the nucleus and cytosol, to stay nuclear and 
induce gene expression. The cytosolic IKK holoenzyme, which we’ll call “classical” IKK, 
contains a regulatory subunit, “NF-κB essential modifier” (NEMO, also called IKKγ/Fip-3/
IKKAP), and two kinase subunits, IKKα and IKKβ (Figure 2D). NEMO is a non-catalytic 
subunit that tethers IKKα and IKKβ into a regulatory holocomplex and is required for 
ubiquitination reactions that beget protein oligomerization and signaling (Hayden and 
Ghosh, 2008). Activation involves signaling assemblies connecting upstream signal 
generation apparatuses to IKK using ubiquitin modifications as the mortar. The TNF 
receptor (TNFR) induces a well-understood IKK induction process. TNF stimulation of 
TNFR recruits the RIP-1, TRADD, TRAF2, cIAP, TAB, and TAK1 proteins into a 
megacomplex with the linear ubiquitin assembly complex (LUBAC) stabilized by linear and 
K63-linked polyubiquitin chains (Dondelinger et al., 2016). Then IKK is incorporated, 
causing ubiquitination of NEMO and phosphorylation of IKK that induce its kinase activity 
(Hayden and Ghosh, 2008). The specific composition of the megacomplex depends on 
specific ubiquitin modifications. This, in turn, determines whether TNFR engagement 
causes NF-κB induction and survival or an alternative fate in which recruitment of RIP 
kinases 1 and 3 induce cell death instead of NF-κB (Dondelinger et al., 2016). The RIP 
protein family, RIPs 1–7, are adaptors and kinases that transmit signals from a wide variety 
of surface receptors and intracellular stress sensors to transcriptional mediators including 
Jnk, Erk, and p38 and NF-κB as well as mediators of necrotic death (Meylan and Tschopp, 
2005). Generally, these transduction complexes can send pleiotropic parallel signals besides 
NF-κB to coordinate necessary responses.
B and T lymphocytes induce NF-κB in adaptive immune responses through the 
CARD11:Bcl10:MALT1 (CBM) complex (Hayden and Ghosh, 2008). Newly expressed 
genes promote lymphocyte proliferation and specific immune functions including antibody 
production by B cells and the generation of cytokines and other anti-pathogen responses by 
T cells. Abnormalities of immune activation can foster immunodeficiency, autoimmune 
diseases, or lymphoid malignancies. The CBM complex is the shared central conduit of T-
cell receptor (TCR) and B cell receptor (BCR) signaling essential for NF-κB (Blonska and 
Lin, 2011; Hayden and Ghosh, 2012). After receptor engagement, CARD11 (CARMA1) is 
recruited and phosphorylated by PKC-θ in T cells and PKC-β in B cells. In T cells, 
CARD11 nucleates the tripartite CBM on the inner leaflet of the membrane by attracting 
BCL10 and the paracaspase MALT1 (Hayden and Ghosh, 2012). Caspase-8 is recruited as a 
full-length, unprocessed, but weakly active form and ropes in IKK to the CBM. MALT1-
dependent tethering of TRAF6 stimulates polyubiquitination of NEMO and the 
phosphorylation of BCL10, IKKα, and IKKβ. Then, casein kinase 1α brings IKKβ into the 
signaling complex and phosphorylates CARD11 to temper further signaling (Bidere et al., 
2009). CARD9, CARD10 (CARMA3), and CARD14 (CARMA2) can form analogous 
biochemical complexes to activate NF-κB during specialized immunity (Blonska and Lin, 
2011). Which specific CARD protein depends on the receptor and downstream effect. The 
BCL10/MALT1 dimer is shared by all CARDs. In addition to NF-κB, different CBM 
complexes can stimulate c-Jun N-terminal kinase (JNK), mechanistic target of rapamycin 
(mTOR), and other signal pathways (Blonska and Lin, 2011). However, lymphocytes require 
NF-κB. For B lymphocytes, BAFF/BAFF receptor (BAFFR) causes maturation and survival 
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through NF-κB (Gerondakis and Siebenlist, 2010; Mackay and Cancro, 2006). For T 
lymphocytes, many cytokines and their receptors — ones that control and are controlled by 
NF-κB — govern proliferation, specialization into functional subsets, and survival 
(Gerondakis and Siebenlist, 2010).
The rapid and irreversible demolition of IκB proteins in the proteasome - the toggle for NF-
κB – is triggered by phosphorylation and ubiquitination. In the CP, IKKβ phosphorylates 
IκBα on Ser 32 and Ser 36, or IκBβ on Ser 19 and Ser 23. Phosphorylated IκBs are then 
polyubiquitinated by SCFβ–TrCP E3 ubiquitin ligases, the signal for proteasome deposition 
(Ben-Neriah, 2002). Mutation of any of these serines will block IκB degradation and prevent 
signaling. By contrast, the AP utilizes a dimer of IKKα to phosphorylate p100 on serines 
176 and 180 causing proteasomal processing to p52 (Hayden and Ghosh, 2008, 2012). p100 
is mainly complexed with RelB with its AnkR domain as an IκB (sometimes called IκBδ) to 
retain nascent p52 and RelB in the cytoplasm. Phosphorylation of the p100 AnkR domain is 
independent of IKKβ, IKKγ, or the classical IKK complex. Instead, it requires the NF-κB-
inducing kinase (NIK). NIK is unstable and a TRAF complex controls its ubquitination and 
proteasomal turnover. Receptors induce the AP by pulling away the TRAF complex, thereby 
stabilizing NIK so it can phosphorylate IKKα. This causes IKKα to specifically 
phosphorylate the cytoplasmic p100:RelB complex on serines 866 and 870 causing 
ubiquitination and proteolysis of the C-terminal AnkR domain and nuclear ingress of 
p52:RelB (Sun, 2011). Transcription by NF-κB is also enhanced by Rel protein 
phosphorylation (Hayden and Ghosh, 2008). Also, IκBα and IκBε can go to the nucleus and 
recapture DNA-bound NF-κB and halt transcription (Hayden and Ghosh, 2008). Moreover, 
NF-κB induces the IκBα gene establishing a cybernetic negative feedback (Hayden and 
Ghosh, 2012).
The physiological role of NF-κB is best delineated in the immune system. Knockout mice 
for the RHD proteins show predominantly immunological defects (Gerondakis et al., 2006). 
Also, a cornucopia of human genetic disorders affecting NF-κB show prominent immune 
pathology (Courtois et al., 2016). Correspondingly, CP inducers, mainly p50:RelA dimers, 
include all sorts of pro-inflammatory cytokines such as tumor necrosis factor (TNF) and 
interleukin-1 (IL-1), conventional humoral and cellular antigens, pathogen-associated 
molecular patterns (PAMPs) including many bacterial and viral products, cellbound and 
soluble immune mediators, and effector molecules. These potently trigger NF-κB in 
lymphocytes, macrophages, and dendritic cells and other minor immune cell types (Hayden 
and Ghosh, 2008, 2012). Inducing NF-κB turns on thousands of genes that re-sculpt the 
transcriptional program of immune cells from quiescence to a proliferating effector 
phenotype capable of fighting pathogens. The NF-κB-induced genes include nearly the 
entire armamentarium of immune guardians: chemokines, cytokines, adhesion molecules, 
inflammatory mediators, and apoptosis inhibitors, giving NF-κB a pivotal role in global 
immunity (Lenardo et al., 1989).
The AP of NF-κB activation is not regulated by classical IKK or IκBs and therefore doesn’t 
respond to CP inducers (Nishikori, 2005). Whereas the CP responds rapidly to immediate 
infectious threats, the AP has slow and sustained kinetics dependent on new protein 
synthesis consistent with a role in organogenesis (Baltimore, 2011; Hayden and Ghosh, 
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2008). Many inducers are a subgroup of the TNFR superfamily, perhaps any receptor that 
signals through TRAFs, including BAFFR, CD40, RANK, 4-1BB, HVEM, OX40, GITR, 
Fn14, TNFR2, and CD30, each of which likely relates to a different function of the AP 
(Gerondakis and Siebenlist, 2010; Mackay and Cancro, 2006). For example, B-cell-
activating factor (BAFF) drives peripheral B cell differentiation and survival (Mackay and 
Cancro, 2006). CD40, is expressed broadly on immune cells and uses both the AP and CP to 
control B cell activation, maturation, germinal center formation, somatic mutation and class 
switching. Lymphotoxin (LT) and LIGHT trigger the LTβ receptor (LTβR) to mediate 
development of peripheral lymph nodes and Peyer’s patches (Sun, 2011). Finally, RANK 
regulates bone formation and dendritic cell functions through AP signals (Hayden and 
Ghosh, 2008). How each of these distinct responses is conveyed by the p52:RelB dimer is 
unknown. Specific microRNAs, miR-223, miR-15a, and miR-16, are negative regulators of 
IKKα, showing that there exist even more sophisticated regulatory mechanisms for gene 
control (Ma et al., 2011).
As these 30 years have gone on, the field has witnessed discovery of an increasing diversity 
of activators, signaling components, and responding genes for the NF-κB system that are 
updated continuously on the web (Gilmore, 2016 http://www.bu.edu/nf-kb/gene-resources/
target-genes/). The central question persists: how this fairly simple regulatory system can 
respond to an enormous group of inducers and faithfully transpose those into appropriate 
patterns of gene expression in different tissues. A relatively new approach is to examine 
genetic defects affecting NF-κB in humans. Clinicians provide an extraordinarily detailed 
phenotype that can now be combined with whole genome analysis together with exhaustive 
systems analysis using transcriptomics and proteomics. We now review the human genetic 
data and compare it with our current understanding from biochemistry and mouse data.
Human genetics
There are now human genetic diseases affecting a large number of NF-κB components and 
these are summarized in Figure 3 and Table 1.
IκB regulatory complex
1. NEMO—NEMO/IKBKG mutations were the first genetic defects discovered in the NF-
κB pathway and showed unique phenotypes caused by different mutations. Because IKBKG 
is on the X chromosome, disease was more severe in males. Complete loss-of-function 
(LOF), i.e. null or amorphic, mutations cause incontinentia pigmenti (IP) in females and 
prenatal lethality in males except when the latter show mosaicism or an XXY karyotype. 
Thus, it is an essential gene. Hypomorphic mutations cause a different skin disease, 
anhidrotic ectodermal dysplasia with Immunodeficiency (EDA-ID) in males, and mild IP in 
females. The severity of phenotypes dictates that most mutations are de novo.
Amorphic NEMO mutations: IP patients have skin inflammation combined with varying 
abnormalities of hair, nails, teeth, retinal vascularization, and the central nervous system. 
The disease was clinically recognized in the 1920s and genetically linked to Xq28 in the late 
1980s (Wieacker et al., 1985). In 2000, only two years after it was cloned and mapped to the 
same region, NEMO was identified as the causal gene of IP (Smahi et al., 2000). All IP 
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mutations are amorphic. A deletion of exons 4 through 10 of NEMO occurs in 
approximately 65% of IP patients. Only heterozygous female survive. The prominent skin 
lesions suggest a vital role of NEMO and NF-κB in skin cells. Due to X-inactivation/
lyonization, female heterozygotes have half of their skin cells with normal NEMO 
expression and the other half deficient. The defective half die quickly after birth and leave 
behind damaged skin and skewed X-inactivation in the residual keratinocytes. Skewed X-
inactivation in leukocytes also implies that NEMO is essential for their survival.
Hypomorphic NEMO mutations: Milder disease is caused by hypomorphic NEMO 
mutations manifesting as anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) 
(Doffinger et al., 2001). EDA-ID studies also revealed a requirement for NF-κB in 
keratinocyte proliferation and differentiation. A paradox of NEMO deficiency is that the B, 
T, and NK subsets develop normally in most EDA-ID patients, but Ig production is often low 
and severe gram-positive cocci, gram-negative bacilli, or mycobacterial infections lead to 
high mortality at an early age. Studies in patient’s cells showed that defective NEMO 
impairs the CP response to many immune mediators including IL-1β, IL-18, TNF, or LPS 
(Doffinger et al., 2001; Hubeau et al., 2011). TNF signaling stimulates both apoptosis and 
activation pathways. Achieving the appropriate immune response requires the NF-κB 
induction of apoptosis inhibitory genes (Karin and Lin, 2002). Deficiencies of NEMO and 
other pathway components that disrupt NF-κB cause TNF-induced apoptosis to predominate 
which impairs immunity. Interestingly, NEMO-deficient patient cells also responded poorly 
to CD40 ligand (CD40L/CD154) that activates both CP and AP through multiple TRAFs 
possibly predisposing to mycobacterial infections. The NEMO-dependent CP rapidly 
activates NF-κB, as an immediate response to inflammatory stimuli. Conversely, the 
NEMO-independent AP acts slowly and continuously to promote cell maturation and 
differentiation. Thus, dendritic cells (DCs) from NEMO-deficient patients exhibited poor 
production of IL-12 in response to CD40L, while peripheral B cell differentiation dependent 
on CD40L was relatively normal (Filipe-Santos et al., 2006). Moreover, CD40L activates the 
MAPK pathway in a NEMO-and ubiquitination-dependent fashion, revealing NF-κB-
independent functions for NEMO (Elgueta et al., 2009).
NEMO mutations found in EDA-ID are heterozygous, hypomorphic, and have varying 
phenotypes due to effects on different protein domains as well as non-coding regions 
involved in splicing and mRNA stability. There are two broad classes of disease: EDA-ID or 
immunodeficiency without EDA. Mutations causing decreased protein expression, folding, 
or stability, such as mutations in the 5′ untranslated region or exon 1B, usually cause 
immunodeficiency without EDA; the A288G mutation, which affects protein stability, leads 
to EDA-ID. By contrast, mutations that do not affect protein levels, but abolish one of the 
ubiquitin binding sites, lead to EDA-ID (e.g. D306N, D311G, D311N, C417R) (Hubeau et 
al., 2011). Thus, abnormal ubiquitination patterns may cause aberrant signaling complexes 
that affect keratinocyte differentiation in ways that go beyond a simple lack of NEMO 
protein.
2. IKKα/IKK1/IKBKA—The two enzymatic components of the IKK complex, IKKα and 
IKKβ, share 50% overall sequence identity and 65% kinase domain identity but cause 
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drastically different human diseases, neither of which resembles NEMO deficiency (Hayden 
and Ghosh, 2008). IKKα deficiency leads to lethal fetal malformations, whereas IKKβ 
deficiency causes severe combined immunodeficiency (SCID) (Lahtela et al., 2010; 
Pannicke et al., 2013).
Autosomal recessive LOF mutations of IKKα lead to fetal encasement malformation (also 
called Cocoon Syndrome because of the appearance of the fetuses), the most severe and fatal 
phenotype of any NF-κB gene deficiency. IKKα deficiency was confirmed by gene 
expression profiling in aborted fetuses. The severe phenotype of IKKα deficiency is 
surprising because in vitro binding assays show IKKβ has higher affinity for NEMO than 
IKKα and IKKβ can form homodimers and bind to NEMO without IKKα. So, in theory, 
IKKα deficiency should impair the IKK complex less than IKKβ deficiency. It is surprising 
that IKKβ cannot compensate for the lack of IKKα. However, consistent with the in vitro 
assays, ikkα knockout mouse died soon after birth, a slightly milder phenotype than the 
embryonic lethal phenotype of the ikkβ knockout mouse (Gerondakis et al., 2006). Even 
more confounding, mice with an unactivatable mutant but not complete loss of ikkα are 
viable.
Interestingly, LOF mutations of receptor-interacting protein kinase 4 (RIP4) cause the same 
but less severe spectrum of craniofacial, skin, and limb deformities as IKKα LOF mutations, 
in a disease called Bartsocas-Papas syndrome or Popliteal Pterygium Syndrome (Kalay et 
al., 2012). RIP4 is an adaptor for upstream signaling cassettes to the IKK complex with the 
participation of TRAF proteins (Hayden and Ghosh, 2008). Among the seven human RIPs, 
each of which signals to distinct gene induction programs, RIP4 regulates keratinocyte 
differentiation and wound healing through NF-κB. RIP4 mutations produce proteins that are 
catalytically inactive and fail to elicit NF-κB (Kalay et al., 2012). Thus, IKKα mutations 
and RIP4 mutations likely affect NF-κB but the prominent skin manifestations no doubt also 
reflect effects on non-NF-κB pathways. For example, IKKα deficiency also potentially 
reveals NF-κB-independent functions. IKKα can translocate to the nucleus and 
phosphorylate histone H3. It also acts on chromatin independently of its kinase activity 
altering the expression of specific genes, for example 14-3-3δ, which influences the G2/M 
checkpoint. Also, both IKKα and IKKβ regulate β-catenin stability in the Wnt pathway. 
Moreover, nuclear IKKα induces cell cycle arrest and terminal differentiation by regulating 
Smad2/3 target genes (Liu et al., 2012).
3. IKKβ/IKK2/IKBKB—IKKβ-deficient patients appear normal at birth but develop SCID. 
This is strikingly different than knockout mice, which die as embryos due to liver 
degeneration, lung deformation, skin inflammation, and many other dysmorphic features. 
IKKβ deficient patients lack signs of developmental or gene regulatory defects in other 
organs (Gerondakis et al., 2006). This mouse-human discordance indicates a true difference 
in physiological roles because human fibroblasts and peripheral blood cells from patients 
had no detectable IKKβ protein equivalent to a mouse “knockout.” Curiously, patient cells 
also had reduced NEMO and IKKα protein levels despite normal mRNA levels (Mousallem 
et al., 2014; Pannicke et al., 2013), suggesting that IKKβ confers stability on all three 
proteins in the classical IKK complex in humans. This was not seen in ikkβ deficient mice 
(Tanaka et al., 1999).
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IKKβ-deficient patients reveal the biological differences between IKKα and IKKβ. 
Normally, purified classical IKK contains NEMO:IKKα:IKKβ in a 2:1:1 stoichiometry, 
although an alternate IKK composed of NEMO and IKKβ homodimers occurs in T cells 
(Hayden and Ghosh, 2008). IKKα homodimers complexed with NEMO can phosphorylate 
IκB in vitro, although it is uncertain whether they exist in vivo. In IKKβ deficient cells, 
however, IKK incorporates IKKα homodimers which alters responses to certain stimuli. 
Phosphorylation and degradation of IκBα and IL-6 induction were absent to TLR5 
stimulation by flagellin, drastically reduced in response to TNF stimulation, and only 
marginally affected in response to IL-1β (Pannicke et al., 2013). Thus, IKKα homodimers 
can mediate CP signaling for certain NF-κB-activating receptors, perhaps because IKKα 
associates more weakly with NEMO than IKKβ. Receptor selectivity has also been 
confirmed by IKKβ knockdowns in human fibroblasts. Hence, IKKα and IKKβ homodimers 
might serve different receptors. Moreover, the full response to TNF was reconstituted by 
restoring IKKβ in patient cells, confirming that IKKβ has unique functions not compensated 
by IKKα (Pannicke et al., 2013).
Although NF-κB was first discovered for κ light-chain expression, it has proved 
indispensable for many lymphocyte responses (Hayden and Ghosh, 2012). Patients with 
IKKβ deficiency had normal T and B cell development but the activation and proliferation of 
mature T and B cells was severely impaired, fostering a SCID phenotype (Mousallem et al., 
2014). Normal activation and differentiation into effector or memory cells is blocked and 
mostly naive lymphocytes remain. The activation block can be partly overcome by stronger 
stimulation with phorbol myristate acetate (PMA), or phytohemagglutinin (PHA). Patient B 
cells also showed reduced responses to CD40L stimulation with IL-21.
4. IκB family (IκBα)/NFKBIA—IκBα (NFKBIA) is the prototype of the IκB family and 
remains the only one identified in a human monogenic disease (Hayden and Ghosh, 2008). 
All human IκBα mutations are heterozygous gain-of-function (GOF) mutations that 
augment NF-κB inhibition causing autosomal dominant disease that blends the clinical 
features of NEMO and IKKβ deficiency (Courtois et al., 2003; Schimke et al., 2013). As in 
hypomorphic NEMO mutations, EDA is observed. Like IKKβ deficiency, peripheral T cells 
respond poorly to antigen(Courtois et al., 2003). TNF or CD40L evoke little nuclear 
translocation of NF-κB. Thus, the GOF mutations in IκBα have a dominant negative effect. 
A mouse model was generated recently to mimic the heterozygous human S32I IκBα 
mutation. Heterozygous mice develop EDA comparable to human patients, but also lack 
lymph nodes, Peyer’s patches, splenic marginal zones, and germinal centers and exhibit 
significantly decreased responses to TLRs, TNF, LTβR, and BAFF. Thus, mice, unlike 
humans, show impairment of both the CP and AP (Mooster et al., 2015). S
Most dominant interfering NFKBIA mutations are either substitutions affecting the 
phosphorylation of residues Ser32 and Ser36 or N-terminal protein truncations removing 
these serines. The mutant IκBα proteins are expressed but cannot undergo phosphorylation-
driven degradation. Disregarding induction signals, they remain constitutively bound to NF-
κB and freeze the pathway. This has been elegantly verified by overexpressing mutant IκBα 
proteins encoded by patient alleles and showing that they override the wildtype protein and 
block NF-κB-induced gene expression (Courtois et al., 2003). Certain truncation mutations 
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have variable blocking effects perhaps due to differential protein stability or the efficiency of 
utilizing alternative ATG start sites downstream of premature mutant stop codons. For 
example, a very early truncating mutation, E14X, showed strong dominant inhibition due to 
a very efficient internal ATG that facilitated high mutant protein expression (Lopez-
Granados et al., 2008). However, another heterozygous early truncating mutation, W11X, 
showed no dominant negative effect. The IκBα protein from the wild-type allele was 
normally phosphorylated and degraded so that there was only haploinsufficiency of NF-κB 
resulting in a milder disease phenotype (McDonald et al., 2007). Further studies might 
reveal how the kinetics of IκBα degradation, resynthesis, and accumulation of protein from 
the WT allele is affected by the presence of a mutant protein. Recently, a homozygous 
IκBNS/NFKBID mutation has been found in a patient with combined immunodeficiency, 
and marked B and CD8+ T cell lymphopenia (Vanessa Bryant, unpublished data). There are 
no disease associations yet for IκBβ or IκBε.
5. Rel homology domain protein family—Mutations in three of the five RHD protein 
genes: p50 (NFKB1), p65 (RELA), and c-Rel (REL), have been chiefly associated with 
humoral immunodeficiency. The p52 and RelB components of the AP will be discussed 
further below. Heterozygous NFKB1 (p105/p50) gene mutations cause common variable 
immunodeficiency (CVID) (Fliegauf et al., 2015). CVID is milder than SCID, prevails in 
older patients, and manifests as defective antibody responses. Patients with NFKB1 
mutations experience recurrent respiratory infections, hypogammaglobulinemia with low 
IgG, IgM, and IgA (reflecting deficient Ig isotype class-switching), Epstein-Barr virus 
(EBV)-associated lymphoproliferation, low peripheral B cell counts and, occasionally, other 
symptoms such as granulomatous lung disease, neutropenia, and Idiopathic 
thrombocytopenic purpura (ITP). The disease has variable expressivity, a feature commonly 
observed in haploinsufficiency conditions. For example, the father of a young woman with 
severe respiratory infections and EBV-lymphoproliferative disease had the same mutation 
but only mild respiratory symptoms not requiring medical attention (Boztug et al., 2016). In 
large kindreds, heterozygous individuals exhibited widely varying antibody responses, 
infection, lymphoma, or inflammatory bowel diseases (Fliegauf et al., 2015). In 
haploinsufficient immunological diseases, whether this variation in clinical phenotype is due 
to independent genetic variants or environmental influences remains a fascinating question.
NFKB1 mutations cause partial reduction, i.e. haploinsufficiency, of both p105 and p50 in 
the resting state and severely reduced p105 phosphorylation after stimulation (Boztug et al., 
2016). Several multiplex kindreds with splicing or frameshift mutations in NFKB1 caused 
haploinsufficiency in a dominant inheritance pattern due to reduced levels of p105 and p50 
protein indicating that the WT allele cannot ramp up expression to compensate for the 
mutant allele. In other patients, whose heterozygous mutation generated a truncated unstable 
protein, nuclear translocation of NF-κB was impaired by an unknown dominant negative 
mechanism (Fliegauf et al., 2015). Considering that varied RHD dimers exist in 
lymphocytes, changes in p105 or p50 levels might alter the balance of other dimers causing 
surprising outcomes. For example, in the family mentioned above, the father with less severe 
disease had substantially greater levels of p50 and p105 protein than the daughter for 
undiscovered reasons (Boztug et al., 2016). A new study of Finnish families with 
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heterozygous LOF mutations in NFKB1 revealed variants affecting protein stability, subunit 
phosphorylation, or nuclear translocation and causing a wide range of immune disorders 
(Seppanen Mikko, unpublished data).
Completely different clinical phenotypes are found with genetic alterations of the different 
RHD proteins. A heterozygous de-novo nonsense mutation in RELA/p65 is associated with 
lymphadenopathy and idiopathic thrombocytopenic purpura. The mutation results in roughly 
1/2 of the normal protein expression, but how haploinsufficiency leads to abnormal 
lymphocyte homeostasis and autoimmunity is still under investigation (Comrie and Lenardo, 
unpublished observations).
6. CARD-BCL10-MALT1 signalosome (MALT1, BCL10, CARD9, CARD11, and 
CARD14)—The CBM complex is affected by many genetic defects causing immune 
dysregulation and malignancy. Interestingly, BCL10 and MALT1 deficiencies are similar 
since they generally work together, whereas the clinical disorders caused by deficiencies 
with CARD9, 11, and 14 are different because each plays a different role in immunity.
MALT1: MALT1 (MALT lymphoma translocation protein 1) was first discovered in 
mucosa-associated lymphoid tissue (MALT) lymphoma in 1999 (Dierlamm et al., 1999), in 
which a chromosome translocation spawns a cIAP2-MALT1 fusion gene that constitutively 
activates NF-κB. Members of 3 families with LOF MALT1 mutations show CID, 
enteropathy, and severe eczema together with dysmorphic features. Most patients have 
hypogammaglobulinemia but paradoxically increased levels of IgE, termed hyper-IgE. T 
regulatory cell (Treg) counts were decreased causing autoimmune features. Patient cells 
showed impaired NF-κB responses to PMA + ionomycin, PHA, and anti-CD3 stimulation 
marked by decreased BCL10 cleavage and IκBα degradation leading to immunodeficiency 
(Charbit-Henrion et al., 2016; Jabara et al., 2013). How specific gene expression changes 
cause the particular confluence of immunodeficiency and autoimmunity has not been 
explained.
MALT1 harbors a death domain (DD) and is distantly homologous to caspases in its C-
terminal domain which confers caspase-like proteolytic function. Its substrates include 
BCL10, NIK, RELB, CYLD and A20, all of which are key NF-κB regulators. MALT1 
enzymatic activation is induced by dimerization and substrate engagement, rather than 
processing as a zymogen like conventional caspases. Caspase function both promotes and 
inhibits specific NF-κB functions (Hachmann and Salvesen, 2016). Human mutations are 
found throughout the CARD, paracaspase, and Ig-like domains and they are all LOF 
(Charbit-Henrion et al., 2016; Jabara et al., 2013). These defects resemble the phenotypes 
found in the malt1 knockout mouse (Ruefli-Brasse et al., 2003). However, 5 out of 6 
MALT1-deficient patients also had inflammatory disorders especially enteropathy (Charbit-
Henrion et al., 2016). Inflammation is absent from malt1 knockout mice but emerged in 
genetically engineered paracaspase-dead mice indicating enzyme deficiency is involved (Yu 
et al., 2015).
BCL10: BCL10 deficiency, identified in one patient, resembles MALT1 deficiency (Torres 
et al., 2014). The consanguineous patient exhibited CID and autoimmunity with 
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gastroenteritis, recurrent respiratory viral infections, and oral candidiasis. Lymphocyte 
counts were normal but exhibited overwhelmingly naive phenotypes and undetectable Tregs, 
implying disturbed CP activation. Patient fibroblasts showed impaired NF-κB responses to 
LPS (TLR4), zymosan (TLR2/6), and poly(I:C) (TLR3), marked by decreased nuclear 
translocation and deficient IL-6 and IL-8 production, hence innate immunity also failed. 
Interestingly, patient mononuclear cells showed normal innate responses which was a 
surprising difference in wiring between humans and mice because bcl10 knockout mice 
display impaired NF-κB in macrophages and DCs following innate stimuli.
CARD9: CARD9 deficiency illustrates how NF-κB connects different receptors and 
adaptors to specific cellular responses (Glocker et al., 2009). Homozygous nonsense (LOF) 
mutations in CARD9 were first found in a large consanguineous family and caused recurrent 
fungal infections especially in the brain. More recently, a large variety of patients with 
CARD9 deficiencies have been reported and they consistently show severe fungal infections 
especially rare deep dermatophytoses and central nerve system candidiasis. The patients 
carried LOF mutations such as stop-gain nonsense codons as well as missense mutations, 
although not all missense mutations have been tested rigorously for functional effects. 
Typically disease onset was in childhood, however, some patients presented in adulthood 
illustrating that there might be modifying genes or environmental influences involved 
(Lanternier et al., 2015).
A molecular understanding of the human phenotypes emerges from mouse knockout studies 
showing that CARD9 transduces NF-κB signals from Dectin-1 and Dectin-2, two receptors 
that recognize Candida albicans in unicellular and hyphal forms, respectively. If either 
receptor is activated, signaling through the SYK kinase leads to sequential assembly of the 
CARD9 CBM complex and downstream NF-κB signaling (Blonska and Lin, 2011). Cells 
from a patient with a p.Y92H variant in the CARD domain showed impaired 
phosphorylation of IκBα after stimulation with zymosan, a Dectin-1 inducer. However, 
when mutant and wildtype CARD9 proteins were co-expressed with BCL10 and MALT1, 
they both assembled CBM complexes. Therefore, it is still controversial whether the NF-κB 
signaling defect in the CARD9 deficient patient cells is CBM-dependent or not. Moreover, 
CARD9-deficient cells showed blunted GMCSF responses mediated by the ERK signaling 
pathway, reminiscent of defects in neutrophil killing and recruitment defects reported in 
CARD9 deficient patients (Gavino et al., 2016). CARD9 deficient patients also have 
decreased Th17 T cells, which are crucial for controlling mucosal, but not systemic 
candidiasis (Glocker et al., 2009).
CARD11/CARMA1: In 2006, CARD11, together with MALT1, were found to be targeted 
by somatic mutations that induce constitutive activation of NF-κB and survival signals for a 
particular subtype of human Diffuse Large B Cell Lymphoma (DLBCL) (Ngo et al., 2006) 
(see below). CARD11 missense mutations are found in 9.6% of DLBCL tumor biopsies. 
Introducing the mutant CARD11 into lymphoma cell lines constitutively induces NF-κB 
(Lenz et al., 2008) (see below). Germline CARD11 mutations can cause very different 
disease phenotypes. GOF mutations cause BENTA disease (B-cell expansion with NF-κB 
and T-cell anergy), whereas LOF mutations cause SCID. Families with hypomorphic, 
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dominant negative CARD11 mutations also have significant atopic disease, including atopic 
dermatitis, allergy, high IgE and eosinophils, asthma, and immunodeficiency (Milner, J, 
Snow A, and Gelfand E. personal communication). Each disease provides a window into 
CBM signalosome function and potential therapeutic strategies (Greil et al., 2013; Snow et 
al., 2012).
The discovery of BENTA disease fits with the idea that CARD11 was a bona fide oncogene 
in DLBCL. Four different autosomal dominant GOF germline mutations of CARD11, 
G116S, E127G, G123D, and C49Y, have been discovered in 4 different families 
(Buchbinder et al., 2015; Snow et al., 2012). Three affect the CC domain and one variant, 
C49Y, is located in the N-terminal CARD. The mutant proteins aggregate, colocalize with 
MALT1, activate IKK, increase nuclear localization of NF-κB and transcription (Buchbinder 
et al., 2015; Snow et al., 2012). The germline mutations in the CC and CARD domains 
recapitulated or were identical to the somatic DLBCL mutations (Lenz et al., 2008). The 
germline GOF mutations resulted in polyclonal, sometimes even monoclonal, B cell 
lymphocytosis, expansion of transitional B cells, and hyper-responsiveness of B cells to 
BCR stimulation, CD40L, and BAFF, all through NF-κB. Similar to B cells, T cells from 
BENTA patients also showed spontaneously aggregated CARD11 and NF-κB activation. 
However, peripheral T cells were not expanded and poorly responsive to TCR stimulation, 
likely due to anergy mechanisms (Snow et al., 2012). Although BENTA patients did not 
develop T cell lymphocytosis and T cell lymphoma, GOF mutations of CARD11 have been 
detected in adult T-cell leukemia/lymphoma (ATLL) and in a form of cutaneous T-cell 
lymphoma (CTCL) called Sezary syndrome (Juilland and Thome, 2016). Also, one BENTA 
patient developed B cell chronic lymphocytic leukemia (Snow et al., 2012). The somatic and 
germline GOF mutations appear to be driver mutations indicating that CARD11 may be a 
promising therapeutic target for BENTA plus other lymphoid malignancies.
However, the discovery of CARD11 LOF mutations tells a different story. Patients with 
homozygous recessive LOF CARD11 mutations display severe immunodeficiency with 
predominantly naive T and B lymphocytes and a block in B cell maturation. Antibody 
production by B cells and cytokine production and proliferation by T cells are severely 
impaired (Greil et al., 2013; Stepensky et al., 2013). Patient lymphocytes showed essentially 
no degradation of IκBα or p65 phosphorylation in response to TCR or BCR stimulation 
(Stepensky et al., 2013).
Overall, the clinical and biochemical features of MALT1, BCL10, and CARD11 LOF 
mutations are similar, testimony to synergistic functions in the CBM. One characteristic 
feature of SCID caused by CBM deficiency is that the patients can have normal peripheral T 
and B cell counts, yet a predominantly naive lymphocyte phenotype indicative of failed TCR 
and BCR responses. Thus, there appear to be different requirements for NF-κB signaling in 
lymphocyte ontogeny and mature lymphocytes. The recent report of somatic reversion in a 
CARD11 LOF mutation patient, who presented as Omenn syndrome, underscored this point. 
In this patient, a second-site somatic reversion changed the original germline mutation 
(p.C150*) to a missense mutation (p.C150L), which partly restored CARD11 function. The 
somatic mutation appeared only in a subclone of T cells indicating a survival and expansion 
advantage conferred in a founder cell by reinstating NF-κB signaling. However, the 
Zhang et al. Page 13
Cell. Author manuscript; available in PMC 2018 January 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
expansion of a single T-cell clone perturbed immune homeostasis and led to massive T cell 
infiltration into the skin causing progressive eczema and erythroderma, accompanied by 
lymphadenopathy and hepatosplenomegaly. Furthermore, the oligoclonal T cells did not 
provide sufficiently broad immune protection against uncontrolled CMV infections and 
multiple bouts of sepsis caused by Staphylococcus aureus, Enterococcus, and Pseudomonas 
that eventually proved fatal to the child at 16 months of age (Fuchs et al., 2015).
CARD14: CARD14, a less well-studied member of the CARD-family, nucleates an 
alternative CBM complex and is the apparent causative gene in two related diseases: 
psoriasis 2 (PSORS2) and Familial Pityriasis Rubra Pilaris (PRP), a psoriasis variant that 
chiefly affects hair follicles (Fuchs-Telem et al., 2012; Jordan et al., 2012). Dominant GOF 
mutations lead to psoriasis with or without arthritis. GOF mutations in CARD14 can also 
lead to generalized pustular psoriasis (Sugiura, 2014). A coding SNP in CARD14 (R820W) 
has been associated with sporadic (non-congenital) psoriasis in a meta-genome-wide 
association study (GWAS) (Tsoi et al., 2012).
The discovery of heterozygous CARD14 mutations selectively in psoriatic diseases revealed 
an unexpected function of CARD14 in keratinocytes and innate immunity. CARD14 was 
thought to mediate NF-κB signaling like other CARD proteins. However, the specific skin 
manifestations are due to keratinocyte and not immune cell expression. More intriguingly, 
the CARD14 mutations increase expression in skin causing NF-κB hyperactivation in skin 
cells. Some patient mutations displayed autonomous activation in luciferase assays, whereas 
others showed increased TNF responses. However, CARD14 increases and NF-κB 
hyperactivation have also been observed in psoriasis without CARD14 mutations (Harden et 
al., 2015). Thus, these features may be a cause or consequence of psoriatic skin lesions or 
both.
7. LUBAC complex and its regulators (HOIL1, HOIP, A20, OTULIN, and CYLD)
—Ubiquitination is a crucial post-translational protein modification governing NF-κB 
pathways [8, 113]. Many pathway components, including NEMO, IκBs, p100, and adaptors 
such as MALT1 and BCL10 rely on specific types of regulatory and degradative 
ubiquitination (Iwai, 2014). Specifically, non-degradative or “regulatory” ubiquitination is 
the attachment of polyubiquitin (joined at K63 residues) to signaling proteins. As mentioned 
above, this provides the reversible “glue” that facilitates the multiprotein complexes 
obligatory for NF-κB activation. Certain ubiquitin reactions are facilitated by TRAF 
proteins. The CP may also involve linear ubiquitin modifications catalyzed by the “linear 
ubiquitin assembly complex” (LUBAC) (Sasaki and Iwai, 2015). The enzyme holocomplex 
is composed of three key proteins. HOIL-1 interacting protein (HOIP) is the E3 ligase. 
Haem-oxidized IRP2 ubiquitin ligase-1 (HOIL1) and SHARPIN (SHANK-associated RH 
domain interacting protein) complete the active LUBAC complex that generates Methionine 
1-linked linear polyubiquitin chains in the presence of several E2s to specifically during CP 
activation (Tokunaga, 2013). NEMO is a LUBAC target but there may be multiple, perhaps 
overlapping, ubiquitination processes in NF-κB activation (Sasaki and Iwai, 2015). Negative 
feedback for NF-κB activation is arbitrated by several deubiquitinases, including CYLD 
(CYLD lysine 63 deubiquitinase), OTULIN (OTU deubiquitinase with linear linkage 
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specificity), and A20/TNFAIP3 (TNF alpha induced protein 3) (Tokunaga, 2013). Except for 
SHARPIN, all the other proteins in the LUBAC complex and its regulators are associated 
with monogenic diseases.
HOIL1: HOIL1/RBCK1 deficiency was found in three patients from two unrelated families 
with immunodeficiency, autoinflammation and amylopectinosis, a glycogen storage disease 
that causes liver failure. CP impairment accounted for the invasive pyogenic bacterial 
infections, but did not explain the autoinflammation and amylopectinosis. The mutations 
were autosomal recessive LOF leading to no detectable HOIL1 protein and decreased 
LUBAC complex stability. NEMO ubiquitination in response to TNF or IL-1 stimulation 
was defective. Consequently, less NEMO was recruited to the RIP1 or IRAK-1 adaptor 
proteins in cytokine receptor signaling complexes, IKK was underphosphorylated, and IκB 
degradation was delayed. HOIL1 overexpression in patient cells rescued the protein levels of 
HOIP and SHARPIN and generated a durable LUBAC complex which improved signaling 
(Boisson et al., 2012).
The mechanisms of autoinflammation and amylopectinosis in HOIL1 deficient patients were 
further investigated using Hoil1 knockout mice. These showed spontaneous amylopectin-
like deposits in the myocardium, susceptibility to Listeria monocytogenes, Toxoplasma 
gondii, and Citrobacter rodentium infections, but not spontaneous autoinflammation 
(MacDuff et al., 2015). Immunodeficiency associated with this molecule affects innate 
immunity, because Hoil1 deficiency in Rag1-deficient mice with no lymphocytes still 
created a susceptibility to Listeria infection. Surprisingly, hoil1−/− mice displayed enhanced 
control of MHV68 and Mycobacterium tuberculosis infections compared to wildtype mice. 
Both serum IL-6 and TNF levels were increased in infected mice, which was also evident in 
HOIL1-deficient patients thereby providing insight into the autoinflammatory disorder. How 
defects in the LUBAC complex lead to dramatically variable susceptibilities to different 
pathogens is unknown. The animal models showed that chronic viral infections in the 
hoil1−/− mouse protected them from Listeria infection, possibly due to the increased 
production of the cytokines IL-6, TNF, and IL-12, which enhanced the ability of 
macrophages to kill Listeria (MacDuff et al., 2015). Therefore, HOIL1 deficiency in mice 
and humans revealed a homeostatic balance between inflammation and immune protection.
HOIP: A single case of autosomal recessive deficiency of HOIP has been reported, which 
provides unique information regarding the biological functions of HOIP since the hoip−/− 
mouse is embryonic lethal (Boisson et al., 2015; Peltzer et al., 2014). The HOIP patient has 
a homozygous missense mutation, which severely impaired LUBAC stability. Consequently, 
this patient phenocopies the HOIL-1 deficient patients with susceptibility to infections, 
amylopectinosis, and autoinflammation.
The biochemical defects in the HOIP deficient patient were different from the HOIL-1 
deficient patients, although it might be difficult to draw conclusions based on a single patient 
with a missense mutation. The HOIP deficient patient showed severely decreased linear 
ubiquitination, decreased phosphorylation of IKK, and slightly delayed IκB degradation in 
response to IL-1β and TNF. However, when stimulated with CD40L, the patient B cells 
showed no NF-κB signaling, indicated by a failure of IKK phosphorylation and IκBα 
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degradation. As a result, the patient’s B cells failed to induce CD27 or CD38 when activated 
with CD40L/IL-21. Interestingly, the defects in the patient B cells resembled CD40-deficient 
patients, suggesting that the CD40-CD40L signaling, at least in the CP, requires LUBAC. 
Although both IL-1β and TNF and induced NF-κB signaling were impaired in HOIP 
deficient cells, the defect in IL-1β was more severe than TNF, a phenomenon also observed 
in HOIL-1 deficient cells (Boisson et al., 2015).
A20/TNFAIP3: A20/TNFAIP3 is a ubiquitin removal enzyme regulating NF-κB [123–125]. 
It contains a C-terminal OTU (Ovarian Tumor) domain, which mediates its de-ubiquitylating 
(DUB) activity and seven zinc fingers (ZFs) that harbor its E3 ubiquitin binding and 
cleavage activities. A20 expression is induced by NF-κB and then decreases NF-κB 
signaling as a negative feedback loop. A20 reverses multiple NF-κB signaling pathways by 
cleaving the K63-linked polyubiquitin chains on activated RIP1, RIP2, TRAF6, TBK1, and 
NEMO. A20 also inhibits ubiquitin chain synthesis by blocking the binding of E2 and E3 
proteins (Ma and Malynn, 2012). A20 also negatively regulates Nlrp3 inflammasome 
signaling by suppressing Nlrp3, proIL-1b, and proIL-18 production (Duong et al., 2015; 
Vande Walle et al., 2014). Thus, A20 connects NF-κB regulation to a broader spectrum of 
inflammation functions.
Nucleotide variants in A20 are associated in GWAS with multiple autoimmune diseases, 
including systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis, type 1 
diabetes, coeliac disease, Crohn’s disease, coronary artery disease in type 2 diabetes, and 
systemic sclerosis (Ma and Malynn, 2012). A20 mutations were identified in a monogenic 
syndrome that resembled Behcet’s disease, an autoinflammatory disease involving mucosal 
ulcers and eye inflammation (Zhou et al., 2016). All of the mutations were heterozygous and 
either frameshift or nonsense, which led to haploinsufficient A20 expression. After TNF 
stimulation, patient lymphocytes and fibroblasts showed increased K63-ubiquitinated 
NEMO, increased phosphorylation of IκBα and IKKs, and prolonged nuclear NF-κB. The 
patients had elevated serum TNF, IP-10, IL-17, IL-9, IFN, and IL-6. Similar to A20-
deficient mice, the patients also had greater levels of pro IL-1β, NLRP3 and activated 
caspase-1 and increased production of mature IL-1β after LPS stimulation. Treatment with 
an IL-1 inhibitor, Anakinra, reversed systemic inflammation (Zhou et al., 2016). Additional 
patients with heterozygous missense mutations were discovered shortly after the first report, 
which raised the possibility that the mutant protein was dominant negative but this is not yet 
verified (Ohnishi et al., 2016; Shigemura et al., 2016).
OTULIN: OTULIN is another deubiquitinase that cleaves the N-terminal methionine-linked 
polyubiquitination chains generated by LUBAC (Keusekotten et al., 2013). Four families 
with homozygous mutations of OTULIN had autosomal recessive inflammatory disease with 
recurrent nodular panniculitis with fever and neutrophil infiltration, lipodystrophy, diarrhea, 
joint swelling, and failure to thrive. The mutations severely decreased protein levels and 
deubiquitinase activity. Patient cells showed persisting IKK activity and IκBα 
phosphorylation in response to TNF stemming from a lack of NEMO deubiquitination. 
Patients had increased cytokine profiles resembling the A20 deficient patients. Interestingly, 
conditional deletion of otulin in myeloid cells, but not T or B cells, causes systemic 
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inflammation, neutrophil infiltration, and multi-organ inflammation in mouse models. 
Treatment with anti-TNF neutralizing antibodies ameliorated inflammation in patients and 
rescues mouse phenotypes, indicating that TNF is a key driver of the systemic disease 
(Damgaard et al., 2016). Considering the similar biochemical defects and cytokine profiles 
in A20 deficient and OTULIN deficient patients, TNF or IL-1 blockers may be an effective 
treatment.
CYLD: CYLD (cylindromatosis protein) was first mapped to chromosome 16q12-13 in 
1995 by the familial skin cylidromatosis phenotype (Biggs et al., 1995). Later, a large cohort 
of cylidromatosis patients helped to identify CYLD as a tumor suppressor gene and NF-κB 
regulator (Bignell et al., 2000). CYLD contains three cytoskeletal-associated protein-
glycine-conserved (CAP-GLY) domains that function as a deubiquitinating enzyme that 
targets key molecules such as NEMO. Moreover, CYLD contains a USP catalytic domain 
that acts on ubiquitin at specific lysine residues, and a molecular triumvirate of Cys601-
His871-Asp889 in the α1 helical subdomain that mounts a nucleophilic attack on K63 
residues in polyubiquitin.
The major biological function revealed by CYLD-deficient patients is the control of cell 
growth as indicated by profound cylindromatosis (Brooke-Spiegler syndrome), a benign 
tumor of the sweat glands around the head, face, and neck (Mathis et al., 2015). CYLD 
mutations are also associated with another skin disease, multiple familial trichoepithelioma, 
type 1 (MFT1), characterized by numerous firm skin papules that are trichoepitheliomas 
(follicular tumors) (Farkas et al., 2016). Why so many different CYLD mutations produce 
tumors of skin origin is not known. CYLD was first found to deubiquitinate NEMO, which 
inhibits the CP (Kovalenko et al., 2003). CYLD has been proposed to shape both adaptive 
and innate immunity by regulating TCR, BCR, and TLR signaling (Mathis et al., 2015). 
However, CYLD deficiency yields very different phenotypes compared to insufficiency of 
A20 and OTULIN even though both CYLD and OTULIN can operate together to regulate 
the LUBAC complex.
The difference may lie in the ability of CYLD to govern cell proliferation, which may not 
relate to its NF-κB regulatory function. For example, CYLD deficiency may cause 
overexpression of the c-myb oncogene as a feature of cylindromas (Corda and Sala, 2016). 
However, in addition to NEMO, activated CYLD can remove the lysine 63-linked 
polyubiquitin chains of BCL-3 (an atypical IκB), thus preventing BCL-3 translocation into 
the nucleus together with p52 and p50, which may also promote cell proliferation. 
Keratinocytes defective in CYLD showed increased nuclear translocation of BCL-3, p52, 
and p50 after chemical or UV treatment (Massoumi et al., 2006). Therefore, CYLD not only 
regulates the activation of canonical NF-κB in conditions of infection and inflammation, it 
also suppresses cell proliferation under stress conditions.
8. Caspase-8 (CASP8)—CASP8 deficiency revealed a surprising role for this enzyme in 
the NF-κB pathway. This was only verified when conditional knockouts in lymphocytes 
were made since the germline deficiency in mice is embryonic lethal (Lemmers et al., 2007). 
CASP8 belongs to the cysteine-aspartic acid protease (caspase) family and has a well-
established role in the apoptosis signaling cascade from death receptors such as Fas (Price et 
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al., 2014). However, rare patients with autosomal recessive disease were found to have 
homozygous LOF CASP8 mutations (Chun et al., 2002). The disease involved 
lymphadenopathy, splenomegaly, and defective CD95/FAS-induced apoptosis of peripheral 
blood lymphocytes. In addition, unlike related patients with the autoimmune 
lymphoproliferative syndrome, the disease also included immunodeficiency with recurrent 
sinopulmonary and herpes simplex virus (HSV) infections. T, B, and NK cells from patients 
responded poorly to stimuli through TCR, BCR, and Fc receptors (Niemela et al., 2015).
The immunodeficiency observed in the patients led to the discovery of CASP8 as a 
facilitatory molecule in the NF-κB pathway. During antigen receptor signaling, CASP8 is 
indispensable for full NF-κB induction and gene transcription by linking the IKK complex 
to IκBα in preparation for the phosphotransfer reaction. Consistently, CASP8-deficient 
patient cells showed severely impaired NF-κB nuclear translocation in responses to immune 
stimuli, however normal responses to CD40L stimulation (Su et al., 2005). Two more 
patients found recently confirmed the immunodeficiency but also broadened the phenotype 
with late-onset multi-organ lymphocytic infiltration with granulomas (Niemela et al., 2015). 
Why does CASP8 LOF gives a live human phenotype, whereas in mice it is embryonically 
lethal key? This is likely due to the highly homologous Caspase-10 gene that can function 
during embryogenesis in humans which has been lost in evolution in the mouse genome (Su 
and Lenardo, 2008).
Alternative pathway
9. NIK—Two NIK/MAP3K14 deficient patients were identified in one consanguineous 
family using next generation sequencing (NGS). The patients suffered recurrent and severe 
bacterial, viral and Cryptosporidium infections. Immune phenotyping showed multiple 
lymphocyte defects, including B cell lymphopenia, reduced class-switched memory B cells, 
impaired B cell survival, impaired ICOSL expression, defects in follicular helper T cells 
(Tfh) and memory T cells, and malfunctioning NK cells. This indicates that the triggering 
kinase for the AP greatly influences key lymphocyte functions.
The LOF mutation found in these patients abolished kinase activity against IKKα, 
(Willmann et al., 2014). The phenotype of patients was different from the NIK knockout 
mouse because it lacked the severe structural defects in lymph nodes, Peyer’s patches, 
splenic and thymic structures found in the latter (Yin et al., 2001). Nonetheless, bone 
marrow chimeras and conditional lymphocyte knockout mouse models recapitulated the 
patient phenotype, including decreased memory T cells, disrupted B cell maturation and 
activation, and defective DCs and NK cells (Brightbill et al., 2015; Katakam et al., 2015; 
Noma et al., 2015; Rowe et al., 2013). These results imply that NIK action in non-
hematopoietic tissues is crucially different in humans and mice.
10. NFKB2/p100/p52—Heterozygous NFKB2/p100/p52 mutations have been identified in 
an autosomal-dominant type of CVID, complicated with autoimmunity and endocrine 
deficiency. The patients exhibited recurrent respiratory infections, hypogammaglobulinemia, 
alopecia areata, an autoimmune infiltration of the scalp that causes hair loss, and, frequently, 
adrenal insufficiency. They manifest poor antibody responses, predominantly unswitched 
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naive B cells in the periphery, and some reports of T and NK cell activation defects (Chen et 
al., 2013; Lee et al., 2014; Lougaris et al., 2015). In resting lymphocytes, the NFKB2 protein 
predominantly exists as the p100 precursor form. Upstream signaling, especially TRAF3, 
activates NIK and IKKα dimers, which in turn phosphorylate the two regulatory serines in 
the NRD domain (S866 and S870). Consequently, the canonical acceptor site (K856) is 
ubiquitinated, which leads to the limited processing of p100 to p52 in the proteasome (Sun, 
2012). So it is no surprise that all the mutations found so far (p.R853*, p.R853Afs*29, 
p.K855Sfs*7, p.D865G, p.D865Vfs*17, p.A867V, p.A867Cfs*19) affect the NRD domain 
and either substitute amino acids adjacent to S866, S870, K856, or remove the C-terminus 
that harbors these residues. These mutations abrogate the processing of p100 to p52 before 
or after CD40-CD40L signaling (Chen et al., 2013; Lee et al., 2014). The D865G mutation 
has a dominant effect over the wildtype protein. It interferes with the CP by blocking TNFα-
induced NF-κB nuclear translocation (Lee et al., 2014). Unprocessed p100 can function as a 
CP inhibitor by excessive dimerization with p65 (Basak et al., 2007), which might explain 
how NFKB2 mutations cause effects similar to NFKB1 deficiency in terms of immune 
abnormalities. However, individuals carrying NFKB2 N-terminus mutations acting in a GOF 
manner present with a more severe CID phenotype (Hyesun Kuehn and Sergio Rosenzweig, 
unpublished data). Further investigation of these mutations may elucidate the dominant 
inheritance of the disease as well as the pathogenesis of the adrenal disorder.
11. RELB—Autosomal recessive RELB deficiency has been discovered in three patients 
from the same consanguineous family. The patients presented as CID from infancy, with 
recurrent infections, severe autoimmune skin diseases, and failure to thrive (Mericoa et al., 
2015; Sharfe et al., 2015). The homozygous, LOF mutations led to absence of RELB 
expression but normal levels of other NF-κB/Rel proteins. Interestingly, the patient’s T cells 
exhibited increased p65 nuclear translocation and hyperactivation in response to TCR 
stimulation, whereas B cells showed decreased c-Rel nuclear translocation after CD40 
stimulation (Mericoa et al., 2015). This implies a cell-specific homeostatic balance between 
the CP and AP. Moreover, the T and B cell defects in RELB deficient patients were not 
observed in relb knockout mice which had inflammatory and hematopoietic abnormalities 
(Gerondakis et al., 2006; Sun, 2012).
12. TRAFs and specific NF-κB pathways—The TRAF (Tumor necrosis factor 
receptor associated factor) family proteins connect receptors to both the CP and AP, as well 
as multiple other pathways (Hayden and Ghosh, 2008). There are seven TRAFs, which link 
various receptors to downstream pathways to induce specific signals. The six typical TRAF 
members (TRAF1-6) share similar functional domains, including a C-terminal TRAF 
domain that mediates homodimerization and interactions with other proteins, a zinc finger 
domain, and a RING finger domain with E3 ubiquitinase ligase activities (except for 
TRAF1). TRAFs 2,3,5, and 6 have E3 ubiquitinase ligase activity.
TRAFs are well-studied signaling adapters for the TNF receptors (TNFRs). They either 
directly bind the TRAF-interacting motif in the cytoplasmic domain of the TNFRs, or bind 
indirectly via other adaptor proteins like TRADD (TNFR1-associated death domain protein), 
which tethers them to specific TNFRs with cytoplasmic death domains. Upon binding to the 
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receptors, TRAFs recruit and activate downstream signaling molecules such as TAK1 and 
IKK. TRAFs also have ubiquitinase activity. This function is particularly important in the 
AP to control the level of NIK. In cells prior to activation signals, TRAF induces 
ubiquitination of NIK by forming a complex with the E3 ligase cIAP. Activation leads to the 
degradation of TRAFs, which fosters NIK accumulation and AP activation.
The two TRAFs associated with monogenic diseases illustrate the biological functions of the 
entire pathway. Mutations affecting components in the same pathway produce similar 
phenotypes in patients. Mutations in the TLR3-TRIF-TRAF3-TBK1 pathway cause HSV 
encephalitis whereas those in the EDA-EDAR-EDARADD-TRAF6 pathway lead to EDA 
(also known as Hypohidrotic ectodermal dysplasia, HED) (Trzeciak and Koczorowski, 
2016), which resembles hypomorphic NEMO mutations.
TRAF3 and the TLR3 signaling: TRAF3 (Tumor necrosis factor receptor associated factor 
3)
TRIF/TICAM1 (toll like receptor adaptor molecule 1)
TLR3 (Toll like receptor 3)
TBK1 (TANK binding kinase 1)
Mutations in TLR3, TRIF, TRAF3, and TBK1 cause patients to be highly susceptible to 
HSV (Herpes simplex virus) encephalitis, despite robust health otherwise. This is an 
astonishingly specific presentation considering the broad function of the pathway (Guo et 
al., 2011; Herman et al., 2012; Perez de Diego et al., 2010; Sancho-Shimizu et al., 2011). 
TLR3 recognizes dsDNA in a broad range of tissues and cell types. When activated by 
dsDNA, TLR3 is phosphorylated and forms dimers that bind to TRIF to trigger the 
downstream signals. The TLR3-TRIF complex recruits TRAF3, TBK1, and IKKε, which 
activates IRF3. The TLR3-TRIF complex also recruits RIP1, TAB2, and TAK1 and then 
phosphorylates IKK to activate the CP. In fact, the TLR3-TRIF complex supplies a common 
node for several signaling pathways, which together mediate essential antiviral responses in 
the brain (Lafaille et al., 2012). Patient cells defective of the TLR3-TRIF-TRAF3-TBK1 
pathway show impaired activation of both IGF3 and NF-κB and decreased production of 
both IFN and IL-6. Both IRF3 and NF-κB seem to contribute greatly to the antiviral 
responses. On one hand, patients with IRF3 mutations share the susceptibility to HSV 
encephalitis (Andersen et al., 2015). On the other hand, NEMO deficiency also creates 
susceptibility to HSV encephalitis (Audry et al., 2011).
TRAF6 and the EDA signaling: EDA (ectodysplasin A)
EDAR (ectodysplasin A receptor)
EDARADD (EDAR associated death domain)
TRAF6 (Tumor necrosis factor receptor associated factor 6)
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Mutations in EDA, EDAR, EDARADD, and TRAF6 all manifest EDA/HED with a clinical 
phenotype similar to patients with hypomorphic NEMO mutations, although they lack 
immunodeficiency (Headon et al., 2001; Kere et al., 1996; Wisniewski and Trzeciak, 2012a, 
b). EDA, which belongs to the tumor necrosis factor family, is expressed on the ectoderm 
interfollicular cells. EDA activates EDAR on the surface of follicular cells in mesenchyme, 
which in turn binds to EDARADD and TRAF6 to induce downstream signaling. The EDAR-
EDARADD-TRAF6 complex recruits TAB1, TAB2, and TAK1, which activate the CP by 
IKK phosphorylation. The fact that EDA-EDAR-EDARADD-TRAF6-NEMO mutations all 
present as EDA/HED revealing a prominent function in ectoderm development (Trzeciak 
and Koczorowski, 2016). Although TRAF6 has been implicated in multiple NF-κB 
pathways, sometimes synergistic with TRAF3, the disease due to TRAF6 mutations shows 
no resemblance to syndromes due to other NF-κB components including TRAF3. The 
exclusive dependence of EDA signaling on TRAF6, together with the exclusive dependence 
of TLR3 signaling on TRAF3, demonstrates that different receptors ignite specific responses 
through the common NF-κB signaling complexes. This specificity is still poorly understood 
at the molecular level.
14. Other monogenic diseases associated with NF-κB pathways
Immunodeficiency and dysregulation: Mutations in MYD88 (myeloid differentiation 
primary response 88) and IRAK4 (interleukin 1 receptor associated kinase 4) cause 
clinically indistinguishable phenotypes, characterized by life-threatening, recurrent pyogenic 
bacterial infections, especially by invasive pneumococci (Picard et al., 2003; von Bernuth et 
al., 2008). Patient cells exhibit failures in multiple TLRs (including TLR2, TLR3, TLR4, 
TLR5, TLR9) and two IL-1Rs (IL-1R and IL-18R). The activation of NF-κB and JNK 
pathways downstream of these signals were absent, demonstrated by the absence of IκB 
degradation and JNK phosphorylation, and this led to decreased IL-6 and IFN-β. This fits 
with cellular data showing that MYD88 and IRAKs mediate signaling from almost all TLRs 
(except for TLR3) and interleukin-1 receptor and related receptors (IL-1Rs). Patient cells 
showed a broad range of defects in response to stimulation of these receptors. This includes 
poor responsiveness to poly(I:C) which is thought to be recognized by TLR3. Mouse 
knockout models showed a broad vulnerability to essentially all pathogens tested (common 
bacteria, virus, parasites, and fungi). However, the restricted susceptibility to pyogenic 
bacteria indicates a more specialized function in humans.
Developmental disorders: TAK1/MAP3K7 (mitogen-activated protein kinase kinase kinase 
7) is a member of the serine/threonine protein kinase family. TAK1 unites with TRAF6, 
TAB1, and TAB2 to induce NF-κB signaling. It also activates JNK in responses to TGF-β 
signaling. Mutations in TAK1 have been clinically associated with Frontometaphyseal 
Dysplasia (FMD), a progressive skeletal dysplasia affecting the long bones and skull (Basart 
et al., 2015; Wade et al., 2016).
TAB2 (TAK1-binding protein 2) is also a part of the TRAF6-TAB1/2-TAK1 complex, which 
activates NF-κB and JNK signaling in responses to TGF-β. This explains why TAB2 
deficiency has been clinically associated with congenital heart defects including unusual 
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valve dysplasia and Tetralogy of Fallot rather than a prominent immune phenotype (Weiss et 
al., 2015).
RIPK4/RIP4 (receptor interacting serine/threonine kinase 4) is a serine/threonine protein 
kinase that interacts with protein kinase C-delta. In the balance of inflammation vs. 
nonapoptotic cell death that characterizes the RIP family of kinases, RIP4 tips towards NF-
κB signaling for inflammation especially in skin cells. Mutations in RIPK4 are associated 
with Popliteal pterygium syndrome (Bartsocas-Papas type). It is considered to be a close 
resembling of IKKα deficiency, which we discussed in section 2 (Kalay et al., 2012).
TRAPPC9/NIBP (trafficking protein particle complex, subunit 9/NIK and IKBKB-binding 
protein) was originally identified as a NIK and IKKβ interacting protein, which enhances the 
cytokine-induced NF-κB. The mutations in TRAPPC9 cause mental retardation (autosomal 
recessive type 13) (Mir et al., 2009; Mochida et al., 2009). However, the disease is more 
likely to be associated with the function of TRAPPC9 in the TRAPP complex (trafficking 
protein particle complex), which regulates the vesicle trafficking of ERgolgi, intra-golgi, and 
endosome-golgi trafficking (Hu et al., 2005; Zong et al., 2011).
Cancer
Somatic mutations, ones that arise in individual cells as a person ages, in genes affecting 
NF-κB have roles as “drivers” of the oncogenic process in specific malignancies. These 
mutations have two principle effects: stimulation of proliferative pathways and inhibition of 
apoptosis, affecting malignant cells together with supporting stroma and blood vessels. 
There are also corollary effects by NF-κB on inflammation and immunity that promote 
favorable niches for cancer cells to take root and expand. NF-κB involvement in the 
pathogenesis of a wide variety of tumors, anti-tumor immunity, and cancer therapies is 
reported in thousands of publications, so we will focus only on the principle malignancy of 
lymphoid cells, lymphoma, to illustrate a few important concepts. NF-κB is deranged in 
lymphomas by somatic mutations as well as by oncogenic viruses such as Epstein-Barr 
virus. One instructive example is the role of NF-kB in the “activated B cell” (ABC) subtype 
of diffuse large cell B cell lymphoma (DLBCL) (Young et al., 2015). DLBCL is the most 
prevalent lymphoid cancer and the ABC subtype is highly aggressive and resists 
chemotherapy. Constitutive NF-κB activation is “conditionally essential” meaning that the 
transformation phenotype requires it and without it, ABL lymphoma cells die (Bidere et al., 
2009). Nontransformed B cells have no such requirement. This is one of the key concepts. 
When the conditions of transformation are wired into lymphoma cells of this subtype, 
certain pathways become turned on and the cell becomes dependent, even addicted, to this 
adrenaline rush of molecular stimulatory pathways for growth and survival. NF-κB, which is 
normally quiescent and dependent on very specific molecular signals, is turned on in an 
unrelenting drive towards a self-enforcing ABC lymphoma gene expression pattern. Key to 
uncontrolled lymphoma growth is an anti-apoptotic transcriptional program, with boosted 
expression of apoptosis inhibitors such as Bcl-2. This underpins the resistance of these 
malignancies to chemotherapeutic agents, which provoke apoptosis to have their toxic effect. 
Constitutive deregulation of NF-κB predictably alters other regulators such as Bcl-6, 
PRDM-1, IRF-4 and others, to give the specific B cell phenotype.
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ABC cells lines may be paradigmatic of other forms of hematopoietic cancers in that 
experimental elimination of a whole range of NF-κB signaling wires including IKKβ, 
CARMA1, BCL10, MALT1 (or its caspase activity), or LUBAC components induce 
programmed death of the cancer cell. The same has been observed when removing 
components of the BCR signal generation apparatus including CD79A, CD79B, Btk, Syk, 
Blnk, PLCγ2, PKCβ. Hence, the life of an ABC lymphoma cell depends on inducing and 
maintaining active NF-κB. A principal culprit behind unrelenting NF-κB activation is BCR 
clustering reminiscent of the antigen-engaged receptor. The putative triggering antigen has 
not been identified but plausible candidates are endogenous autoantigens (Young et al., 
2015). In addition, enhanced TLR signaling due to mutations in MyD88 and IRAK1 further 
aggravate uncontrolled NF-κB in ABC-DLBCL. Finally, mutations inactivating A20 and 
potentially other down-modulators add even more fuel to the NF-κB conflagration. Hence, 
entire pathways used in normal immune function become reconfigured in the service of 
malignancy. Also, the mutations that activate these pathways and induce NF-κB are selective 
in generating ABC-DLBCL; other variants, such as the “germinal center B cell” (GCB) form 
of DLBCL does not show these characteristic mutations and does not depend on NF-κB 
(Pasqualucci and Dalla-Favera, 2015). Germline mutations that promote NF-κB activation 
may also create an inherited or de novo predisposition to the development of ABC 
lymphoma. The key oncogenic role of NF-κB is evident in other types of lymphoma, 
especially Burkitt’s lymphoma, caused in part by EBV which induces NF-κB through its 
LMP-1 function (Neoptolemos et al., 2010). Finally, genes encoding RHD NF-κB proteins 
or their key signaling proteins are common at breakpoints of chromosomal translocations in 
lymphomas and leukemias (Nishikori, 2005).
NF-κB as a therapeutical target
Given its key role in immunity, cancer, and other aspects of human physiology, the concept 
prevails that NF-κB should be a valuable pharmaceutical target. In fact, drugs already 
marketed, such as raloxifene, apparently exert therapeutic effects by inhibiting NF-κB 
(Olivier et al., 2006). The widespread involvement in signaling means that many drug targets 
exist in the relevant pathway components and a single successful drug may have utility in 
multiple diseases. The centrality of NF-κB in innate and adaptive immune receptor signaling 
suggests that NF-κB inhibitory drugs could be widely efficacious against autoimmune and 
lymphoproliferative disorders. However, these crossover effects may also be a harbinger of 
unexpected adverse side effects. Inhibition of NF-κB with test therapeutics has been found 
to cause unexpected, even counterintuitive, effects such as neutrophilia, fever, and abnormal 
IL-1 release. We will illustrate this paradox with drug development in cancer. Since NF-κB 
inhibits apoptosis and this is obligatory for cell survival, for example, in ABC-DLBCL 
lymphoma, then blocking NF-κB should be an effective treatment (Young et al., 2015). 
Furthermore, upregulated NF-κB promotes cell proliferation, metastasis, metabolic changes 
and other abnormalities that favor the expansion and spread of malignancy (Kim et al., 2006; 
Perkins, 2012). Thus, strategies to suppress NF-κB have been clinically tested, most 
prominently proteasome blockers and IKK inhibitors. Bortezimib (Velcade) is approved for 
multiple myeloma, a plasma cell malignancy, whose aggressiveness depends in part on NF-
κB (Kim et al., 2006). Also, thalidomide and other putative IKK inhibitors have been 
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successful in myeloma. These agents, however, have been thwarted by side effects 
potentially due to NF-κB suppression including nephrotoxicity, neuropathy, and also the 
relapse of more aggressive forms of malignancy (Mina et al., 2016). Finally, as the pivotal 
role of the immune system in fighting malignancy has come into focus with new discoveries 
in immunotherapy, NF-κB inhibition is cast into a new light (Couzin-Frankel, 2013). Potent 
NF-κB inhibitors may emasculate T cells that antigenically recognize and kill tumor cells, 
thereby worsening disease. Thus, the broad role of NF-κB in cellular regulation makes its 
druggability complicated.
Conclusions and Future Perspectives
In the 30 years that we have known about the seminal roles NF-κBs, much has been learned 
about their biochemical properties, their responses to signaling events and their 
physiological roles. Given the enormous number of genes activated by NF-κBs and the 
diverse modes of signaling that impinge upon these transcription factors, there remains much 
to learn. Most of the basic work on NF-κB was done in mice and their cells. However, by 
taking advantage of the striking phenotypes of human mutants in NF-κBs and their related 
proteins, we can now generate data on the roles of NF-κB in human biology and compare 
that to mouse data. As this review shows, that has proven very useful.
The many investigators seeking human mutations have now found defects in almost all of 
the core molecules in the NF-κB pathways. This provides a rich set of tools to study 
signaling and transcription in humans by proteins related to infection and inflammation. 
Studies in humans that correlate biochemical alterations with physiological defects are 
difficult to perform but these “experiments of nature” offer the opportunity to make these 
connections.
It is striking how often the effects in humans differ from those in mice when similar or even 
identical mutations are compared. This is a testament to how evolution has used these 
proteins in different ways in the two species. In many cases, we do not know precisely what 
these differences are: they may be quantitative or qualitative. Because NF-κB is involved in 
infection control and the pathogens impinging on the lives of humans and mice are so 
different, evolution would appear to have adapted to the precise requirements of the two 
species. If similar work were possible with more species, an increasing richness of 
specificity would presumably emerge.
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Figure 1. 
The NF-κB paradigm of timely and flexible biochemical control of cell behavior.
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Figure 2. 
A. Rel homology domain proteins in the NF-κB protein family and the v-Rel oncoprotein. 
The N-terminal regions of REL family proteins share the Rel homology domain (RHD), 
which has amino acid similarity to the product of the v-rel oncogene from the 
Reticuloendotheliosis virus REV-T and a nuclear localization sequence (NLS). RelB has a 
leucine zipper (LZ) and RelA, RelB, and c-Rel, harbor a transactivation domain (TAD). 
p105 and p100 have 5–7 tandem ankyrin repeats (AnkR) and a death domain (DD). 
Regulatory phosphorylation sites (P) and ubiquitination sites (Ub) are shown. B. Inhibitors 
of NF-κB (IκB) family of proteins. The eight described IκBs are characterized by their 5–7 
tandem ankyrin repeats (AnkR) which mediate binding to NF-κB dimers. The N-terminal 
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regions of the classical IκBs (IκBα, IκBβ, IκBε) contain two serine residues (P), which 
permit the accelerated ubiquitination (Ub) and degradation of the protein when 
phosphorylated. BCL3 has similar modification residues but IκBζ and IκBNS do not. The 
C-terminal regions of p105 and p100 function as IκBs for their linked RHD even before 
processing by forming large complexes with Rel proteins, including p50 and p52. PEST: 
Region rich in the amino acids proline, glutamic acid, serine, and threonine. DD: death 
domain. C. Structure of the IκB:NF-κB latent complex (PBD 1NFI). Ribbon diagram of the 
crystal structure of the isolated complex including IκBα (blue), showing its anchor and 
repeat domain (ARD) and PEST sequence rich in the amino acids proline, glutamic acid, 
serine, and threonine that acts as a signal for protein degradation, p50 (red), and the RelA 
(green), inter-domain linker, and N-terminal domain (NTD). D. IKK complex. Shown are 
the components of the IKK complex including two kinases: IKKα, IKKβ, and the non-
enzymatic subunit NEMO. CC1: Coiled-coil domain 1; CC2: Coiled-coil domain 2; LZ: 
Leucine zipper; Zn: Zinc-finger; Kinase: Kinase domain; HLH: Helix-loop-helix region; 
NBD: NEMO-binding domain. Regulatory phosphorylation sites (P) and ubiquitination sites 
(Ub) are shown. The number of amino acids (aa) of each protein is shown at right. Adapted 
from (Hayden and Ghosh, 2008, 2012).
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Figure 3. The major monogenic diseases in the core pathways of both the classical (CP) and 
alternative (AP) pathways of NF-κB signaling
Color coded boxes indicate the main feature of diseases.
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